Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

17 January 2019 : Animal Research  

Different Triple-Negative Breast Cancer Tumor Cell Lysates (TCLs) Induce Discrepant Anti-Tumor Immunity by PD1/PDL-1 Interaction

Bohan Dong123ABCDEFG, Yuanyuan Ding2B, Qianwu Huang2B, Xiaoxiang Guan14AEG*

DOI: 10.12659/MSM.911689

Med Sci Monit 2019; 25:500-515

Abstract

BACKGROUND: TCL-based immunotherapy has been applied in the field cancer therapy. However, it is un clear whether this therapy can be used to treat triple-negative breast cancer (TNBC), and different TNBC cells have distinct responses to this therapy.

MATERIAL AND METHODS: In the present work, we conducted 2 different TCL-based immunotherapies to treat TNBC and compared their anti-tumor effect on 4 TNBC cell lines: MDA-MB-231, MDA-MB-436, HCC1937, and HCC1187.

RESULTS: Peripheral blood mononuclear cells (PBMC) activated by TCL and peripheral blood lymphocytes (PBL) stimulated with TCL-loaded DC demonstrated the ability to kill TNBC cells in vitro, but the killing efficiency of PBL was much higher than that of PBMC. In vivo, PBL stimulated with TCL-loaded DC can also stop the growth of TNBC tumors in mice. HCC1187 and MDA-MD-231 best respond to TCL-based immunotherapy both in vitro and in vivo. The response of HCC1937 was weaker, and that of MDA-MB-436 was lowest among the 4 cell lines. Total mRNA microarray analysis of TNBC cells showed that PDL-1 mRNA expression in HCC1937 and MDA-MD-436 cells was higher than in the other 2 TNBC cell lines, and that of MDA-MB-436 was higher than that of HCC1937. PD1 blocking can decrease the apoptosis rate. These results show that different contents of PDL-1 in TCL, by interacting with PD expression on lymphocytes, can induce different ratios of lymphocyte apoptosis, and then result in distinct response of the 4 TNBC cell lines to TCL-based immunotherapy.

CONCLUSIONS: TCL-based immunotherapy has discrepant anti-tumor efficiency in different TNBC cell lines by PDL-1/PD interaction, providing the theoretical basis of TCL-based immunotherapy in TNBC.

Keywords: Immunotherapy, Immunotherapy, Active, Triple Negative Breast Neoplasms, B7-H1 Antigen, Leukocytes, Mononuclear, Lymphocytes, Programmed Cell Death 1 Receptor

0 Comments

Editorial

01 March 2023 : Editorial  

Editorial: Global Surveillance of Highly Pathogenic Avian Influenza Viruses in Poultry, Wild Birds, and Mammals to Prevent a Human Influenza Pandemic

Dinah V. Parums

DOI: 10.12659/MSM.939968

Med Sci Monit 2023; 29:e939968

SARS-CoV-2/COVID-19

In Press

24 Mar 2023 : Database Analysis  

Causes of Death Following Gastric Cancer Diagnosis: A Population-Based Analysis

Med Sci Monit In Press; DOI: 10.12659/MSM.939848  

22 Mar 2023 : Special report  

One Year On: Poland’s Public Health Initiatives and National Response to Millions of Refugees from Ukraine

Med Sci Monit In Press; DOI: 10.12659/MSM.940223  

22 Mar 2023 : Clinical Research  

Value of IL-1β and IL-23 in Predicting 28-Day Mortality Due to Sepsis: A Retrospective Study

Med Sci Monit In Press; DOI: 10.12659/MSM.940163  

21 Mar 2023 : Clinical Research  

Efficacy of Direct Anterior Approach Versus Posterior Lateral Approach for Total Hip Replacement in Patient...

Med Sci Monit In Press; DOI: 10.12659/MSM.939682  

Most Viewed Current Articles

13 Nov 2021 : Clinical Research  

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788

30 Dec 2021 : Clinical Research  

Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...

DOI :10.12659/MSM.935379

Med Sci Monit 2021; 27:e935379

08 Mar 2022 : Review article  

A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...

DOI :10.12659/MSM.936292

Med Sci Monit 2022; 28:e936292

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750